Publikationen von Thomas Zander

Sos, M.; Koker, M.; Weir, B.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J. M.; Weiss, J.; Fischer, F.; Frommolt, P. et al.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A. F.; Minna, J. D.; Garraway, L. A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R. K.: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research 69 (8), S. 3256 - 3261 (2009)

Salvesen, H. B.; Carter, S. L.; Mannelqvist, M.; Dutt, A.; Getz, G.; Stefansson, I. M.; Raeder, M. B.; Sos, M. L.; Engelsen, I. B.; Trovik, J. et al.; Wik, E.; Greulich, H.; Bo, T. H.; Jonassen, I.; Thomas, R. K.; Zander, T.; Garraway, L. A.; Oyan, A. M.; Sellers, W. R.; Kalland, K. H.; Meyerson, M.; Akslen, L. A.; Beroukhim, R.: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America 106 (12), S. 4834 - 4839 (2009)

Nogova, L.; Boellaard, R.; Kobe, C.; Hoetjes, N.; Zander, T.; Gross, S. H.; Dimitrijevic, S.; Pellas, T.; Eschner, W.; Schmidt, K. et al.; Bangard, C.; Hayes, W.; Thomas, R. K.; Dietlein, M.; Giaccone, G.; Hoekstra, O. S.; Lammertsma, A. A.; Wolf, J.: Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine 50 (11), S. 1815 - 1819 (2009)

Ullrich, R. T.; Zander, T.; Neumaier, B.; Koker, M.; Shimamura, T.; Waerzeggers, Y.; Borgman, C. L.; Tawadros, S.; Li, H.; Sos, M. L. et al.; Backes, H.; Shapiro, G. I.; Wolf, J.; Jacobs, A. H.; Thomas, R. K.; Winkeler, A.: Early detection of erlotinib treatment response in NSCLC by 3'-Deoxy-3'-[18F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE 3 (12), S. e3908 - e3908 (2008)

Sos, M. L.; Zander, T.; Thomas, R. K.; Staratschek-Jox, A.; Claasen, J.; Wolf, J.: Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. Journal of Thoracic Oncology 3 (2), S. 170 - 173 (2008)

Thomas, R. K.; Baker, A. C.; Debiasi, R. M.; Winckler, W.; Laframboise, T.; Lin, W. M.; Wang, M.; Feng, W.; Zander, T.; Macconnaill, L. E. et al.; Lee, J. C.; Nicoletti, R.; Hatton, C.; Goyette, M.; Girard, L.; Majmudar, K.; Ziaugra, L.; Wong, K.-K.; Gabriel, S.; Beroukhim, R.; Peyton, M.; Barretina, J.; Dutt, A.; Emery, C.; Greulich, H.; Shah, K.; Sasaki, H.; Gazdar, A.; Minna, J.; Armstrong, S. A.; Mellinghoff, I. K.; Hodi, F. S.; Dranoff, G.; Mischel, P. S.; Cloughesy, T. F.; Nelson, S. F.; Liau, L. M.; Mertz, K.; Rubin, M. A.; Moch, H.; Loda, M.; Catalona, W.; Fletcher, J.; Signoretti, S.; Kaye, F.; Anderson, K. C.; Demetri, G. D.; Dummer, R.; Wagner, S.; Herlyn, M.; Sellers, W. R.; Meyerson, M.; Garraway, L. A.: High-throughput oncogene mutation profiling in human cancer. Nature Genetics 39 (3), S. 347 - 351 (2007)

Thomas, R. K.; Sos, M. L.; Zander, T.; Mani, O.; Popov, A.; Berenbrinker, D.; Smola-Hess, S.; Schultze, J. L.; Wolf, J.: Inhibition of nuclear translocation of nuclear factor-kappa B despite lack of functional I kappa B alpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. Clinical Cancer Research 11 (22), S. 8186 - 8194 (2005)